Drug intelligence / Profile preview

electroconvulsive therapy + α-ethyltryptamine

Development stage
Unknown
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of two distinct interventions: - **Electroconvulsive therapy (ECT)** is a psychiatric procedure in which controlled electric currents are passed through the brain under general anesthesia to induce a brief seizure. ECT rapidly improves symptoms of severe mental health conditions such as major depressive disorder, bipolar disorder, and catatonia when other treatments have failed. Its mechanism involves altering brain chemistry and promoting neuroplasticity[2][3][4]. - **α-Ethyltryptamine (AET or αET)** is a synthetic entactogen and stimulant from the tryptamine family. Originally developed as an antidepressant under the brand name Monase by Upjohn in the 1960s, it was withdrawn due to toxicity concerns. AET acts primarily as a serotonin-norepinephrine-dopamine releasing agent and weak serotonin receptor agonist; it also has weak monoamine oxidase inhibitory properties[1][5]. It has been studied for depression and schizophrenia but is now controlled due to abuse potential.

Brand names
Monase
Other names
electroconvulsive therapyα-ethyltryptamineetryptamine
02

Targets

HTR2A (Serotonin receptor 5-HT2A)SERT (Sodium-dependent serotonin transporter)NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)

Beyond the preview

Go deeper on electroconvulsive therapy + α-ethyltryptamine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on electroconvulsive therapy + α-ethyltryptamine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call